World-first pill for postpartum depression could be rolled out in US by AUGUST
Health chiefs are poised to approve the first-ever pill made specifically for women dealing with post-partum depression.
Massachusetts-based drugmakers Sage Therapeutics and Biogen said Monday the Food and Drug Administration (FDA) could approve the medication by August 6.
The medication zuranolone is an antidepressant drug that patients only need to take for two weeks. This is a stark contrast to the other medication on the market for postpartum depression (PPD), a drug called Zulresso, which needs to be administered via IV continuously for 60 hours.
Postpartum depression plagues about one in seven new mothers. Symptoms can be debilitating, from deep despair and frequent crying to thoughts of hurting the baby, not feeling connected to the baby, or feeling as if your baby is someone else’s.
Increased focus has been put on the condition in recent weeks after Boston mother Lindsay Clancy, 32, allegedly murdered her three children after suffering from an extreme form of postpartum psychosis.
